NCT03236428 2026-03-27Phase II Study of the CD38 Antibody Daratumumab in Patients With High-Risk MGUS and Low-Risk Smoldering Multiple MyelomaDana-Farber Cancer InstitutePhase 2 Active not recruiting42 enrolled 8 charts
NCT03820817 2025-04-20Rifaximin in Patients With Monoclonal GammopathyEmory UniversityPhase 1 Active not recruiting50 enrolled